Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the Study and Treatment of Pain;Utilisation des opioïdes forts dans la douleur chronique non cancéreuse chez l'adulte. Recommandations françaises de bonne pratique clinique par consensus formalisé (SFETD)

Presse Medicale

Volumn 45, Issue 4, 2016, Pages 447-462

  Moisset, Xavier ^a   Trouvin, Anne Priscille ^b   Tran, Viet Thi ^c   Authier, Nicolas ^d   Vergne Salle, Pascale ^e   Piano, Virginie ^f   Martinez, Valeria ^g  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e UNIVERSITY OF LIMOGES   (France)

^f Centre hospitalier de La Dracénie   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; AWARENESS; BACKACHE; CHRONIC NON CANCER PAIN; CHRONIC PAIN; DRUG EFFICACY; DRUG INDICATION; DRUG MISUSE; DRUG RELEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; EVIDENCE BASED MEDICINE; EXTENDED DRUG RELEASE; FIBROMYALGIA; FRENCHMAN; HUMAN; MEDICAL SOCIETY; MEDICAL SPECIALIST; META ANALYSIS (TOPIC); NEUROPATHIC PAIN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PATIENT CARE; PRESCRIPTION; PRIMARY HEADACHE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; NEOPLASM;

ADULT; ANALGESICS, OPIOID; CHRONIC PAIN; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS;

EID: 84962711693     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2016.02.014     Document Type: Article

References (109)

1. [1] France. Sénat (1958-.) N, L. (1994). Prendre en charge la douleur. Journaux officiels, 1994.
2. [2] Perrot, S., Bannwarth, B., Bertin, P., et al. Utilisation de la morphine dans les douleurs rhumatologiques non cancéreuses : les recommandations de Limoges. Rev Rhum 66 (1999), 651–657.
3. [3] Vergne-Salle, P., Laroche, F., Bera-Louville, A., et al. Les opioïdes forts dans les douleurs ostéo-articulaires non cancéreuses : revue de la littérature et recommandations pour la pratique clinique : « Les recommandations de Limoges 2010 ». Douleurs 13 (2012), 259–275.
4. [4] Martinez, V., Attal, N., Bouhassira, D., et al. Les douleurs neuropathiques chroniques : diagnostic, évaluation, traitement en médecine ambulatoire. Recommandation pour la pratique clinique de la Société française d’étude et de traitement de la douleur. Douleur Analg 23 (2010), 51–66.
5. [5] Betses, M., Brennan, T., Abusive prescribing of controlled substances–a pharmacy view. N Engl J Med 369:11 (2013), 989–991.
6. [6] Edlund, M.J., Martin, B.C., Fan, M.Y., et al. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend 112 (2010), 90–98.
7. [7] Okie, S., A flood of opioids, a rising tide of deaths. N Engl J Med 363 (2010), 1981–1985.
8. [8] Sullivan, M.D., Edlund, M.J., Fan, M.Y., et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 138 (2008), 440–449.
9. [9] Franklin, G.M., Opioids for chronic noncancer pain. A position paper of the American Academy of Neurology. Neurology 83 (2014), 1277–1284.
10. [10] HAS, Élaboration de recommandations de bonne pratique. Recommandations pour la pratique clinique. Guide méthodologique. 2010, HAS, Saint-Denis La Plaine.
11. [11] Turk, D.C.O.A., Pain terms and taxonomies., 3rd ed. Wilkins, LW., (eds.) Bonica's management of pain, 2001, Loeser D, Butler SH, Chapman JJ, Turk DC, 18–25.
12. [12] Balshem, H., Helfand, M., Schunemann, H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
13. [13] Farrar, J.T., Young, J.P. Jr., LaMoreaux, L., et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001), 149–158.
14. [14] Guyatt, G., Oxman, A.D., Akl, E.A., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64 (2011), 383–394.
15. [15] Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64 (2011), 395–400.
16. [16] Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines 6. Rating the quality of evidence–imprecision. J Clin Epidemiol 64 (2011), 1283–1293.
17. [17] Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines: 8. Rating the quality of evidence–indirectness. J Clin Epidemiol 64 (2011), 1303–1310.
18. [18] Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines: 7. Rating the quality of evidence–inconsistency. J Clin Epidemiol 64 (2011), 1294–1302.
19. [19] Guyatt, G.H., Oxman, A.D., Montori, V., et al. GRADE guidelines: 5. Rating the quality of evidence–publication bias. J Clin Epidemiol 64 (2011), 1277–1282.
20. [20] Guyatt, G.H., Oxman, A.D., Sultan, S., et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64 (2011), 1311–1316.
21. [21] Guyatt, G.H., Oxman, A.D., Vist, G., et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol 64 (2011), 407–415.
22. [22] Clark, A.J., Ahmedzai, S.H., Allan, L.G., et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20 (2004), 1419–1428.
23. [23] Furlan, A.D., Sandoval, J.A., Mailis-Gagnon, A., et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174 (2006), 1589–1594.
24. [24] Kalso, E., Edwards, J.E., Moore, R.A., et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 3 (2004), 372–380.
25. [25] Noble, M., Treadwell, J.R., Tregear, S.J., Coates, V.H., Wiffen, P.J., et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev, 1(1), 2010.
26. [26] Noble, M., Tregear, S.J., Treadwell, J.R., et al. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 35 (2008), 214–228.
27. [27] Chaparro, L.E., Wiffen, P.J., Moore, R.A., et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev, 7, 2012, CD008943.
28. [28] Eisenberg, E., McNicol, E., Carr, D.B., Opioids for neuropathic pain. Cochrane Database Syst Rev, 3, 2006.
29. [29] Eisenberg, E., McNicol, E.D., Carr, D.B., Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain 10 (2006), 667–676.
30. [30] Finnerup, N.B., Otto, M., Jensen, T.S., Sindrup, S.H., An evidence-based algorithm for the treatment of neuropathic pain. Med Gen Med, 9(2), 2007, 36.
31. [31] McNicol, E.D., Midbari, A., Eisenberg, E., Opioids for neuropathic pain. Cochrane Database Syst Rev, 8, 2013.
32. [32] Snedecor, S.J., Sudharshan, L., Cappelleri, J.C., Sadosky, A., Desai, P., Jalundhwala, Y., et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract 68:7 (2014), 900–918.
33. [33] Wong, M.C., Chung, J.W., Wong, T.K., Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ, 335(7610), 2007, 87.
34. [34] Avouac, J., Gossec, L., Dougados, M., Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 15 (2007), 957–965.
35. [35] Bjordal, J.M., Klovning, A., Ljunggren, A.E., et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 11 (2007), 125–138.
36. [36] Chung, J.W.Y., Zeng, Y., Wong, T.K.S., Drug therapy for the treatment of chronic nonspecific low back pain: systematic review and meta-analysis. Pain Physician 16 (2013), E685–E704.
37. [37] Gehling, M., Hermann, B., Tryba, M., Meta-analysis of dropout rates in randomized controlled clinical trials: opioid analgesia for osteoarthritis pain. Schmerz 25 (2011), 296–305.
38. [38] Martell, B.A., O'Connor, P.G., Kerns, R.D., et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 146 (2007), 116–127.
39. [39] Nuesch, E., Rutjes, A.W., Husni, E., Welch, V., Juni, P., Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev, 4, 2009.
40. [40] Chaparro, L.E., Furlan, A.D., Deshpande, A., et al. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev, 8, 2013, CD004959.
41. [41] Chaparro, L.E., Wiffen, P.J., Moore, R.A., Gilron, I., Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev, 7, 2012.
42. [42] Papaleontiou, M., Henderson, C.R. Jr., Turner, B.J., et al. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 58 (2010), 1353–1369.
43. [43] Buntin-Mushock, C., Phillip, L., Moriyama, K., et al. Age-dependent opioid escalation in chronic pain patients. Anesth Analg 100 (2005), 1740–1745.
44. [44] Chao, J., Retrospective analysis of Kadian (morphine sulfate sustained-release capsules) in patients with chronic, nonmalignant pain. Pain Med 6 (2005), 262–265.
45. [45] Colburn, J.L., Jasinski, D.R., Rastegar, D.A., Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic. J Opioid Manag 8 (2012), 153–160.
46. [46] Collado, F., Torres, L.M., Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain. J Opioid Manag 4 (2008), 111–115.
47. [47] Cowan, D.T., Allan, L., Griffiths, P., A pilot study into the problematic use of opioid analgesics in chronic non-cancer pain patients. Int J Nurs Stud 39 (2002), 59–69.
48. [48] Cowan, D.T., Wilson-Barnett, J., Griffiths, P., et al. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med 4 (2003), 340–351.
49. [49] Fredheim, O.M., Increasing use of opioids for pain. Eur J Pain 18 (2014), 1219–1220.
50. [50] Gatti, A., Longo, G., Sabato, E., et al. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol 65 (2011), 317–322.
51. [51] Gatti, A., Mammucari, M., Sabato, E., et al. Adherence and long-term effect of oxycodone/paracetamol in chronic noncancer pain: a retrospective study. Adv Ther 28 (2011), 418–426.
52. [52] Gore, M., Sadosky, A.B., Leslie, D.L., et al. Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain. Pain Pract 12 (2012), 457–468.
53. [53] Harden, R.N., Gagnon, C.M., Graciosa, J., et al. Negligible analgesic tolerance seen with extended release oxymorphone: a post hoc analysis of open-label longitudinal data. Pain Med 11 (2010), 1198–1208.
54. [54] Jamison, R.N., Link, C.L., Marceau, L.D., Do pain patients at high risk for substance misuse experience more pain? A longitudinal outcomes study. Pain Med 10 (2009), 1084–1094.
55. [55] Katz, N.P., Sherburne, S., Beach, M., et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 97 (2003), 1097–1102 [table of contents].
56. [56] Krebs, E.E., Lurie, J.D., Fanciullo, G., et al. Predictors of long-term opioid use among patients with painful lumbar spine conditions. J Pain 11 (2010), 44–52.
57. [57] Leider, H.L., Dhaliwal, J., Davis, E.J., et al. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care 17 (2011), 32–40.
58. [58] Manchikanti, L., Ailinani, H., Koyyalagunta, D., et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 14 (2013), 91–121.
59. [59] Mystakidou, K., Parpa, E., Tsilika, E., et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 4 (2003), 298–306.
60. [60] Pappagallo, M., Campbell, J.N., Chronic opioid therapy as alternative treatment for post-herpetic neuralgia. Ann Neurol 35 Suppl. (1994), S54–S56.
61. [61] Passik, S.D., Narayana, A.K., Janka, L., Aberrant drug-related behavior observed during a long-term clinical study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. Pain Med, 11, 2010, 320.
62. [62] Portenoy, R.K., Farrar, J.T., Backonja, M.-M., et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 23 (2007), 287–299.
63. [63] Proctor, S.L., Estroff, T.W., Empting, L.D., et al. Prevalence of substance use and psychiatric disorders in a highly select chronic pain population. J Addict Med 7 (2013), 17–24.
64. [64] Rauck, R., Ma, T., Kerwin, R., Ahdieh, H., Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. Pain Med 9:7 (2008), 777–785.
65. [65] Saper, J.R., Lake, A.E. 3rd., Hamel, R.L., et al. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology 62 (2004), 1687–1694.
66. [66] Tassain, V., Attal, N., Fletcher, D., et al. Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 104 (2003), 389–400.
67. [67] Watson, C.P.N., Watt-Watson, J.H., Chipman, M.L., Chronic noncancer pain and the long term utility of opioids. Pain Res Manag 9 (2004), 19–24.
68. [68] Weisner, C.M., Campbell, C.I., Ray, G.T., et al. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain 145 (2009), 287–293.
69. [69] White, K.T., Dillingham, T.R., Gonzalez-Fernandez, M., et al. Opiates for chronic nonmalignant pain syndromes: can appropriate candidates be identified for outpatient clinic management?. Am J Phys Med Rehabil 88 (2009), 995–1001.
70. [70] Stulman, J., Wisnivesky, J., Yamada, E., Chronic opioid therapy in chronic non-cancer pain in primary care: patients, prescribers and long term follow-up. J Gen Intern Med 25 (2010), S238–S239.
71. [71] Radcliff, K., Freedman, M., Hilibrand, A., et al. Does opioid pain medication use affect the outcome of patients with lumbar disc herniation?. Spine 38 (2013), E849–E860.
72. [72] Jensen, M.K., Thomsen, A.B., Hojsted, J., 10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain 10 (2006), 423–433.
73. [73] Roland, C., Joshi, A., Mardekian, J., Walden, S., Harnett, J., Prescription opioid abuse trends from 2005–2010 in a managed care population. J Pain, 13, 2012, S38.
74. [74] Cloutier, C., Taliano, J., O'Mahony, W., et al. Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag 18 (2013), 75–82.
75. [75] Gordon, A., Callaghan, D., Spink, D., et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 32 (2010), 844–860.
76. [76] Hale, M.E., Dvergsten, C., Gimbel, J., Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 6 (2005), 21–28.
77. [77] Katz, N., Rauck, R., Ahdieh, H., et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 23 (2007), 117–128.
78. [78] Vondrackova, D., Leyendecker, P., Meissner, W., et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9 (2008), 1144–1154.
79. [79] Webster, L.R., Butera, P.G., Moran, L.V., et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 7 (2006), 937–946.
80. [80] Gilron, I., Bailey, J.M., Tu, D., et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005), 1324–1334.
81. [81] Hanna, M., O'Brien, C., Wilson, M.C., Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 12 (2008), 804–813.
82. [82] Harke, H., Gretenkort, P., Ladleif, H.U., et al. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Analg 92 (2001), 488–495.
83. [83] Huse, E., Larbig, W., Flor, H., et al. The effect of opioids on phantom limb pain and cortical reorganization. Pain 90 (2001), 47–55.
84. [84] Khoromi, S., Cui, L., Nackers, L., et al. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 130 (2007), 66–75.
85. [85] Raja, S.N., Haythornthwaite, J.A., Pappagallo, M., et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59 (2002), 1015–1021.
86. [86] Rowbotham, M.C., Twilling, L., Davies, P.S., et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348 (2003), 1223–1232.
87. [87] Simpson, D.M., Messina, J., Xie, F., et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007), 588–601.
88. [88] Watson, C.P., Babul, N., Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50 (1998), 1837–1841.
89. [89] Watson, C.P., Moulin, D., Watt-Watson, J., et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105 (2003), 71–78.
90. [90] Wu, C.L., Agarwal, S., Tella, P.K., et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology 109 (2008), 289–296.
91. [91] Zin, C.S., Nissen, L.M., O'Callaghan, J.P., et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain 11 (2010), 462–471.
92. [92] Bruyere, O., Cooper, C., Pelletier, J.P., et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task frce of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 44 (2014), 253–263.
93. [93] Peng, X., Robinson, R.L., Mease, P., et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain, 2014.
94. [94] Fitzcharles, M.A., Faregh, N., Ste-Marie, P.A., Shir, Y., Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res Treat, 2013, 2013.
95. [95] Lanteri-Minet, M., Valade, D., Geraud, G., et al. Guidelines for the diagnosis and management of migraine in adults and children. Rev Neurol 169 (2013), 14–29.
96. [96] Bahra, A., Walsh, M., Menon, S., et al. Does chronic daily headache arise de novo in association with regular use of analgesics?. Headache 43 (2003), 179–190.
97. [97] Friedman, B.W., Kapoor, A., Friedman, M.S., et al. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 52 (2008), 705–713.
98. [98] Wilkinson, S.M., Becker, W.J., Heine, J.A., Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 41 (2001), 303–309.
99. [99] Niscola, P., Scaramucci, L., Vischini, G., et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 11 (2010), 752–758.
100. [100] Bekkering, G.E., Soares-Weiser, K., Reid, K., et al. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. Curr Med Res Opin 27 (2011), 1477–1491.
101. [101] Fredheim, O.M.S., Borchgrevink, P.C., Mahic, M., et al. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. Pain 154 (2013), 2487–2493.
102. [102] Jamison, R.N., Butler, S.F., Budman, S.H., et al. Gender differences in risk factors for aberrant prescription opioid use. J Pain 11 (2010), 312–320.
103. [103] Manchikanti, L., Cash, K.A., Damron, K.S., et al. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician 9 (2006), 215–225.
104. [104] Webster, L.R., Webster, R.M., Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 6 (2005), 432–442.
105. [105] Butler, S.F., Budman, S.H., Fernandez, K.C., et al. Development and validation of the Current Opioid Misuse Measure. Pain 130 (2007), 144–156.
106. [106] Knisely, J.S., Wunsch, M.J., Cropsey, K.L., et al. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse. J Subst Abuse Treat 35 (2008), 380–386.
107. [107] Roux, P., Sullivan, M.A., Cohen, J., et al. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 154 (2013), 1442–1448.
108. [108] Devulder, J., Jacobs, A., Richarz, U., et al. Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain. Br J Anaesth 103 (2009), 576–585.
109. [109] http://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Fentanyl-transmuqueux-Rappel-de-ses-effets-indesirables-et-de-la-necessite-de-bien-respecter-ses-indications-Point-d-Information.